NCT02415907

Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: Male
• Age: 40 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigating the absorption, metabolism and excretion of radio labelled single doses of idalopirdine in healthy men.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	[ethyl-1-14C]-idalopirdine	120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose
DRUG	[benzyl-7-14C]-idalopirdine	120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose

Timeline

• Start date: 2015-04-01
• Primary completion: 2015-06-01
• Completion: 2015-06-01
• First posted: 2015-04-14
• Last updated: 2015-07-20

Locations

1 site across 1 country: United Kingdom